Adults with type 2 diabetes and opioid use disorder who received semaglutide had significantly lower risk for opioid overdose compared with those taking other diabetes medications, a research letter in JAMA Network Open showed.
Results from the cohort study add to the list of potential treatment applications related to the glucagon-like peptide-1 (GLP-1) receptor agonist, but therapeutic benefits for treatment of opioid use disorder require confirmation in randomized studies, according to study investigators.
According to Rong Xu, PhD, a biomedical informatics professor at Case Western Reserve